Milestone Scientific (MLSS) Resumen de Acciones
Milestone Scientific Inc., empresa de tecnología biomédica, patenta, diseña, desarrolla y comercializa tecnologías de diagnóstico e inyección terapéutica y dispositivos de uso médico y dental en Estados Unidos, China y a escala internacional. Saber más
| Puntuación del snowflake | |
|---|---|
| Valoración | 0/6 |
| Crecimiento futuro | 1/6 |
| Rendimiento pasado | 0/6 |
| Salud financiera | 5/6 |
| Dividendos | 0/6 |
Recompensas
Análisis de riesgos
MLSS Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Competidores de Milestone Scientific Inc.
Historial de precios y rendimiento
| Precios históricos de las acciones | |
|---|---|
| Precio actual de la acción | US$0.55 |
| Máximo en las últimas 52 semanas | US$0.68 |
| Mínimo de 52 semanas | US$0.22 |
| Beta | 1.05 |
| Cambio en 1 mes | 37.19% |
| Variación en 3 meses | 69.27% |
| Cambio de 1 año | -4.52% |
| Variación en 3 años | -48.80% |
| Variación en 5 años | -64.55% |
| Variación desde la OPV | -96.12% |
Noticias y actualizaciones recientes
Recent updates
MLSS: Expanding Clinical Adoption And New Capital Raise Will Drive Upside
Analysts have maintained their $1.00 price target for Milestone Scientific, noting only minor adjustments to the discount rate, profit margin assumptions, and future P/E inputs, rather than any broad change in outlook. What's in the News Reaffirmed earnings guidance for 2026, with expected revenue in the range of US$9.8 million to US$10.2 million, citing double digit growth driven by commercial adoption across dental and medical segments.MLSS: Medical Adoption And New Capital Raise Will Support Future Upside
Analysts have adjusted their price target on Milestone Scientific to $1.00, supported by updated assumptions that include a slightly lower discount rate, revised revenue growth and profit margin expectations, and a higher future P/E multiple. What's in the News Reaffirmed earnings guidance for 2026, with expected revenue of US$9.8 million to US$10.2 million, tied to commercial adoption in both dental and medical segments (Corporate Guidance).MLSS: Expanded Share Authorization And Private Placement Will Support Future Upside
Milestone Scientific's analyst price target has been adjusted slightly, with analysts pointing to small refinements in the discount rate, long term profit margin assumptions and future P/E expectations as key drivers of the updated valuation. What's in the News Entered a securities purchase agreement for a private placement of 7,962,963 units at $0.27 per unit, for gross proceeds of about $2.15m.MLSS: Expanded Share Authorization Will Support Future Upside As Guidance And PE Strengthen
Analysts have adjusted their price target on Milestone Scientific to reflect a modest change in the assumed discount rate and profit margin. They are keeping fair value at $1.00 while updating their future P/E outlook to 72.06x based on the latest inputs.MLSS: Expanded Share Authorization Will Support Future Upside As Revenue Guidance Strengthens
Analysts have modestly adjusted their price target on Milestone Scientific to reflect updated views on slightly different revenue growth expectations, profit margin assumptions and a revised forward P/E profile, while keeping the fair value estimate broadly aligned with prior levels in dollar terms. What's in the News Management issued earnings guidance for the year ending December 31, 2026, with expected total revenue in a range of US$9.8 million to US$10.2 million, citing broadening commercial adoption in both dental and medical segments (company guidance).MLSS: Expanded Share Authorization Will Support Future Upside From Current Levels
Analysts have modestly adjusted their price target on Milestone Scientific to reflect updated views on discount rates, profit margins, and future P/E expectations, while keeping the fair value estimate unchanged at $1.00 per share. What's in the News The company filed a Certificate of Amendment to its Restated Certificate of Incorporation in Delaware on March 10, 2026, increasing authorized common stock from 100,000,000 to 125,000,000 (Key Developments).MLSS: Shares Will Likely Rise As Expanded Authorization Supports Undervaluation
Analysts have modestly raised their price target on Milestone Scientific to $1.00. The change reflects slightly higher assumed discount rates and price-to-earnings expectations, along with a marginally lower profit margin outlook in their updated models.MLSS: Shares Will Likely Rise As Share Authorization Supports Undervaluation
Analysts have nudged their price target on Milestone Scientific slightly higher to $1.00, reflecting small tweaks to the discount rate, profit margin assumptions, and future P/E inputs in their models. What's in the News Shareholders ratified the appointment of CBIZCPA P.C. as Milestone Scientific Inc.'s independent auditors for the fiscal year ending December 31, 2025, at the AGM held on December 18, 2025 (Key Developments).MLSS: Shares Will Likely Rise As Increased Share Authorization Supports Undervaluation
Analysts have adjusted their price target on Milestone Scientific to align with updated assumptions around discount rates, profit margins, and future P/E expectations. This has led to a modest shift in the projected valuation range expressed in US$ terms.MLSS: Shares Will Likely Rise As Auditor Approval Supports Undervaluation
Analysts have slightly lifted their price target on Milestone Scientific to around US$1.00, citing small tweaks to their discount rate, profit margin outlook, and a projected future P/E of about 71x as the main drivers of the updated view. What's in the News Shareholders approved CBIZCPA P.C. as Milestone Scientific Inc.'s independent auditor for the fiscal year ending December 31, 2025, at the AGM held on December 18, 2025 (AGM filing).MLSS: Shares Will Likely Rise As Listing Plan Supports Undervaluation
Analysts have made a modest adjustment to their price target on Milestone Scientific, keeping fair value anchored at US$1.00 while fine tuning assumptions around discount rate, revenue growth, profit margin and future P/E to reflect updated views on the company’s risk profile and earnings power. What's in the News At the December 18, 2025 AGM, shareholders approved an amendment to Milestone Scientific's Restated Certificate of Incorporation to increase authorized common shares from 100,000,000 to 125,000,000 (AGM filing).MLSS: Shares Will Likely Rise As Listing Compliance Risks Ease
Analysts have modestly increased their price target on Milestone Scientific to reflect a slightly lower perceived risk in future cash flows, despite trimming long term profit margin assumptions and applying a higher forward earnings multiple. What's in the News Proposed amendment to the Restated Certificate of Incorporation to increase authorized common shares from 100 million to 125 million, expanding potential equity financing capacity (company filing).MLSS: Shares Will Likely Rebound As NYSE Compliance Plan Progresses
Analysts have trimmed their price target on Milestone Scientific from 1.13 dollars to 1.00 dollars, citing slightly slower expected revenue growth and a modestly lower valuation multiple. This is partially offset by stable profit margin assumptions and a marginally reduced discount rate.MLSS: Shares Will Face Key NYSE American Compliance Decision by 2027
Analysts have revised their price target for Milestone Scientific downward from $1.63 to $1.13. They cite lower projected revenue growth and a higher discount rate as key factors influencing their updated outlook.CompuFlo Epidural System Will Unlock New Global Opportunities
The downward revision in Milestone Scientific’s price target reflects materially lower revenue growth expectations, leading to a drop in projected fair value from $2.12 to $1.62. What's in the News Eric C.
CompuFlo Epidural System Will Unlock New Global Opportunities
Strategic partnerships and regulatory approvals are expanding market access for the CompuFlo Epidural System, potentially driving significant revenue growth.Rentabilidad de los accionistas
| MLSS | US Medical Equipment | Mercado US | |
|---|---|---|---|
| 7D | 18.9% | 3.8% | 1.7% |
| 1Y | -4.5% | -10.8% | 20.0% |
Rentabilidad vs. Industria: MLSS superó a la industria US Medical Equipment, que obtuvo un rendimiento del -10.8% el año pasado.
Rentabilidad vs. Mercado: MLSS obtuvo unos resultados inferiores a los del mercado US, que fueron del 20% el año pasado.
Volatilidad de los precios
| MLSS volatility | |
|---|---|
| MLSS Average Weekly Movement | 11.7% |
| Medical Equipment Industry Average Movement | 8.6% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.2% |
| 10% least volatile stocks in US Market | 3.1% |
Precio estable de las acciones: El precio de las acciones de MLSS ha sido volátil durante los últimos 3 meses en comparación con el mercado US.
Volatilidad a lo largo del tiempo: La volatilidad semanal de MLSS(12%) se ha mantenido estable durante el último año, pero sigue siendo superior al 75% de las acciones de US.
Acerca de la empresa
| Fundada | Empleados | CEO | Página web |
|---|---|---|---|
| 1989 | 15 | Eric Hines | www.milestonescientific.com |
Milestone Scientific Inc. es una empresa de tecnología biomédica que patenta, diseña, desarrolla y comercializa tecnologías de diagnóstico e inyección terapéutica y dispositivos de uso médico y dental en Estados Unidos, China e internacionalmente. Opera a través de los segmentos dental y médico. La empresa ofrece The Wand, un dispositivo de pieza de mano desechable de un solo uso para procedimientos dentales que requieren anestesia local bajo los nombres CompuDent y STA Single Tooth Anesthesia System.
Resumen de fundamentos de Milestone Scientific Inc.
| Estadísticas fundamentales de MLSS | |
|---|---|
| Capitalización bursátil | US$46.61m |
| Beneficios(TTM) | -US$4.57m |
| Ingresos (TTM) | US$8.90m |
¿Está MLSS sobrevalorada?
Ver valor justo y análisis de valoraciónBeneficios e Ingresos
| Cuenta de resultados (TTM) de MLSS | |
|---|---|
| Ingresos | US$8.90m |
| Coste de los ingresos | US$2.58m |
| Beneficio bruto | US$6.32m |
| Otros gastos | US$10.89m |
| Beneficios | -US$4.57m |
Últimos beneficios comunicados
Mar 31, 2026
Próxima fecha de beneficios
Aug 14, 2026
| Beneficios por acción (BPA) | -0.052 |
| Margen bruto | 71.03% |
| Margen de beneficio neto | -51.30% |
| Ratio deuda/patrimonio | 35.0% |
¿Cómo se ha desempeñado MLSS a largo plazo?
Ver rendimiento histórico y comparativaAnálisis de la empresa y estado de los datos financieros
| Datos | Última actualización (huso horario UTC) |
|---|---|
| Análisis de la empresa | 2026/08/13 09:44 |
| Precio de las acciones al final del día | 2026/08/13 00:00 |
| Beneficios | 2026/03/31 |
| Ingresos anuales | 2025/12/31 |
Fuentes de datos
Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.
| Paquete | Datos | Marco temporal | Ejemplo Fuente EE.UU. * |
|---|---|---|---|
| Finanzas de la empresa | 10 años |
| |
| Estimaciones del consenso de analistas | +3 años |
|
|
| Precios de mercado | 30 años |
| |
| Propiedad | 10 años |
| |
| Gestión | 10 años |
| |
| Principales avances | 10 años |
|
* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.
A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.
Modelo de análisis y copo de nieve
Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.
Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.
Métricas industriales y sectoriales
Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.
Fuentes analistas
Milestone Scientific Inc. está cubierta por 3 analistas. 2 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.
| Analista | Institución |
|---|---|
| Bruce Jackson | Benchmark Company |
| Anthony Vendetti | Maxim Group |
| James Terwilliger | Northland Capital Markets |